天演药业公布与FDA就1期临床完结会议讨论结果及Muzastotug在MSS结直肠癌临床开发方面关键进展

天演药业Adagene
15 Jul

公司宣布:与美国食品药品监督管理局(FDA)举行的B类会议取得积极成果。天演已收到FDA就其临床开发计划的书面反馈,该计划旨在评估Muzastotug(ADG126)联合默沙东抗PD-1疗法KEYTRUDA®(帕博利珠单抗,200 mg,每3周一次)治疗微卫星稳定型结直肠癌(MSS CRC)的疗效。FDA B类会议核心成果►受试人群:后续试验将入组后线无肝转移的微卫星稳定型结直肠癌(MSS CRC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10